What is Bicara Therapeutics's market cap?

Bicara Therapeutics (BCAX) has a market capitalization of $1.6B and trades on XNAS.

Who are Bicara Therapeutics's competitors?

Bicara Therapeutics's key competitors include Amgen, Eli Lilly and Company, ArriVent BioPharma, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Bicara Therapeutics partner with?

Bicara Therapeutics's notable partners include Merck & Co..

Where is Bicara Therapeutics headquartered?

Bicara Therapeutics is headquartered in United States of America. It has been publicly traded since 2024.

Bicara Therapeutics

BCAX

Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors.

Market cap

$1.68B+231%

Net income-$157.3M-70.4%

Free cash flow-$116.6M-32.0%

EPS (diluted)-$2.78+93.1%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 11, 2026

EPS-$0.93Miss by $0.29

Read the full report

Next report

Aug 11, 2026 (in 2 months)

EPS estimate-$0.80

Financials

Q1 2026

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation & ratios

Valuation

See full

Market cap$1.64B+81.4%

Enterprise value$1.32B+288%

Returns & leverage

See full

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Competitors

By market cap

Eli Lilly$987.23B

Amgen$187.28B

Arcus Biosciences$3.5B

Immunome$2.2B

Nuvation Bio$2.1B

Syndax Pharmaceuticals$1.7B

Bicara Therapeutics$1.6B

ArriVent BioPharma, Inc.$1.6B

By revenue growth

Nuvation Bio+1,206%

Syndax Pharmaceuticals+397%

Arcus Biosciences+67.4%

Eli Lilly+47.4%

Amgen+9.1%

Immunome-63.3%

By net margin

Eli Lilly34.99%

Amgen20.96%

Nuvation Bio-102.06%

Syndax Pharmaceuticals-111.88%

Arcus Biosciences-156.36%

Immunome-5,593.85%

Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. The company utilizes a proprietary platform to create dual-targeting agents that combine monoclonal antibodies with tumor-modulating payloads to enhance efficacy within the tumor microenvironment while minimizing systemic toxicity.

Competitive position

A clinical-stage innovator focusing on bifunctional EGFR/TGF-beta inhibition to address unmet needs in squamous cell carcinomas.

GeographiesGlobal, United States

Customer segmentsOncology patients, Healthcare providers

Business modelR&D intensive, Biotechnology drug development

SuppliersContract manufacturing organizations, Clinical research organizations, Specialized laboratory equipment providers, Raw material suppliers for biologics

CustomersAcademic medical centers, Specialized oncology clinics, Hospitals

CountryUnited States of America

Listed2024

CEOClaire Mazumdar Clemon

SectorPHARMACEUTICAL PREPARATIONS

IndustryPHARMACEUTICAL PREPARATIONS

FilingsSEC EDGAR

Questions, answered.

What is Bicara Therapeutics's market cap?: Bicara Therapeutics (BCAX) has a market capitalization of $1.6B and trades on XNAS.
Who are Bicara Therapeutics's competitors?: Bicara Therapeutics's key competitors include Amgen, Eli Lilly and Company, ArriVent BioPharma, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Bicara Therapeutics partner with?: Bicara Therapeutics's notable partners include Merck & Co..
Where is Bicara Therapeutics headquartered?: Bicara Therapeutics is headquartered in United States of America. It has been publicly traded since 2024.